Neurological

43-58%
Strong

for early-onset epilepsy and epileptic encephalopathy with exome/genome sequencing

System Profile

Yield Comparison

Clinical Dimensions

  • Seizures (early onset)
  • Hypotonia
  • Ataxia
  • Neuropathy
  • Episodic regression
  • Stroke-like episodes
  • Abnormal movements
  • Epileptic encephalopathy
  • Infantile spasms
  • Leukodystrophies
  • Congenital brain malformations
  • Mitochondrial encephalopathy
  • Cerebral palsy without risk factors
  • Abnormal tone (hypotonia or spasticity)
  • Abnormal reflexes
  • Persistent primitive reflexes
  • Ataxic gait
  • Tremor
  • Nystagmus
  • Focal deficits
  • Micro/macrocephaly
  • Movement disorders
  • Early-onset seizures
  • Episodic developmental regression
  • Chronic headaches or migraine-like episodes
  • Abnormal movements
  • Ataxia episodes
  • Sensory changes
  • Elevated lactate/pyruvate
  • Elevated ammonia
  • Abnormal CSF amino acids or neurotransmitters
  • Abnormal VLCFA
  • Abnormal acylcarnitine profile
  • Copper/ceruloplasmin abnormalities
  • MRI with corpus callosum agenesis
  • Dandy-Walker
  • Chiari
  • Cortical dysplasia
  • Heterotopias
  • Leukodystrophy patterns
  • Basal ganglia calcifications
  • Cerebellar atrophy
  • Mitochondrial stroke-like lesions
  • EEG showing epileptic encephalopathy patterns
  • EMG/NCS showing neuropathy or myopathy
  • LP with abnormal neurotransmitters or lactate
  • Evoked potentials delayed
  • Neuropsych testing with global deficits
  • Multiple anti-seizure meds with poor control
  • Paradoxical responses
  • Valproate intolerance (mitochondrial clue)
  • Frequent sedative use for neuro irritability
  • Paradoxical or severe neurologic reactions to standard neuro meds
  • Sedation or agitation out of proportion
  • MH reaction with anesthesia impacting CNS
  • VP shunt placement
  • Chiari decompression
  • Epilepsy surgery
  • Brain biopsy for unexplained lesions
  • PT/OT/ST targeting abnormal tone, coordination, motor planning
  • Repeated therapy across years for neurological deficits
  • VP shunt
  • VNS for seizures
  • Walkers and wheelchairs for neuro disability
  • Adaptive seating
  • Early neurology referral
  • Multiple neuro evaluations
  • Tertiary epilepsy clinic involvement
  • Neurologist recommending genetics for regression/epilepsy
  • Epilepsy
  • Early strokes
  • Movement disorders
  • Neuropathy
  • Dementia
  • Developmental regression
  • Learning issues in multiple relatives
  • Consanguinity
  • Multiple affected siblings
  • No history of trauma, abuse, or toxin exposure explaining neuro deficits
  • Stable environment yet persistent neurologic symptoms
  • Similar issues in siblings
  • Neonatal seizures
  • Floppy infant (hypotonia)
  • Abnormal or high-pitched cry
  • Poor suck/swallow
  • Micro/macrocephaly at birth
  • Early abnormal neuro exam

Red Flag Combinations

Clinical patterns that should prompt consideration of genetic testing

Seizures + developmental delay + hypotonia
Seizures + regression
Stroke-like episodes + lactic acidosis
Early epilepsy + structural brain anomalies
Neuropathy + cardiomyopathy

Screening Decision Pathway

When to consider genetic testing for neurological presentations

        graph TD
          START["Patient Presents with\nNeurological Concerns"] --> SCREEN{"Screen for\nRed Flags"}
          
          SCREEN --> RF1["Abnormal newborn screen for metabolic or neurodege..."]
          
          SCREEN --> RF2["Failed neurologic reflex checks"]
          
          SCREEN --> RF3["Abnormal tone on routine newborn neuro screens"]
          
          
          RF1 --> EVAL{"Multiple\nFlags Present?"}
          
          RF2 --> EVAL{"Multiple\nFlags Present?"}
          
          RF3 --> EVAL{"Multiple\nFlags Present?"}
          
          EVAL -->|Yes| TEST["Order Genetic Testing\n(ES/GS)"]
          EVAL -->|No| MONITOR["Continue Monitoring\nRe-evaluate if New Findings"]
          TEST --> DX["Molecular Diagnosis\n43-58% yield"]
          style TEST fill:#dcfce7,stroke:#16a34a,color:#14532d
          style DX fill:#bbf7d0,stroke:#16a34a,color:#14532d
          style MONITOR fill:#fef3c7,stroke:#d97706,color:#92400e
        

Screening Red Flags

Findings on routine screening that may indicate genetic etiology

  • Abnormal newborn screen for metabolic or neurodegenerative disorders
  • Failed neurologic reflex checks
  • Abnormal tone on routine newborn neuro screens

Exome / Genome Sequencing Indications

Clinical scenarios supporting ES/GS as a diagnostic approach

  • Unexplained early-onset epilepsy
  • Developmental regression
  • Multisystem neurologic involvement
  • Negative first-tier tests (MRI/EEG/microarray)
  • Strong family history of neuro disease

Key Evidence

Published studies supporting genetic testing for neurological conditions

Study Year Type Sample Yield Key Finding
Utility of Exome Sequencing for Diagnosis in Unexplained Ped... 2023 Cohort None 19% 19% diagnostic yield for exome sequencing in unexplained pediatric epilepsy (100...
Early-Life Epilepsies and the Emerging Role of Genetic Testi... 2017 Cohort None None Early-life epilepsies and the emerging role of genetic testing
Clinical exome sequencing for genetic identification of rare... 2014 Cohort 814 26% Clinical exome sequencing yielded 26% overall molecular diagnosis in 814 consecu...
Enhanced diagnostic yield in Meckel-Gruber and Joubert syndr... 2016 Cohort 26 46% 46% diagnostic yield in ciliopathy (Joubert/Meckel-Gruber) families with exome s...
Diagnostic Exome Sequencing Provides a Molecular Diagnosis f... 2016 Cohort 314 38.2% 38.2% positive/likely positive DES yield in epilepsy patients (vs 28.7% without ...
Effectiveness of Whole Exome Sequencing Diagnosis in the Cli... 2018 Review None 16-68% WES diagnostic yield ranges 16-68% across IEM and neurogenetic disorder cohorts ...
Diagnostic Yield of Next-Generation Sequencing Applied to Ne... 2018 Cohort None 36.5% RASopathies NGS panel with functional analysis improved diagnostic yield from 31...
Meta-analysis and multidisciplinary consensus statement: exo... 2019 Meta-Analysis None 36% Meta-analysis of 37 studies establishes ES as first-tier test for NDDs with 36% ...
Updated: 2026-02-24 Curated by: human Status: human reviewed